Researchers at the Oklahoma University Cancer Institute, US, have identified a new gene that causes cancer. The ground-breaking research appears in cancer journal Oncogene.
The gene and its protein, both called RBM3, are vital for cell division in normal cells. In cancers, low oxygen levels in the tumours cause the amount of this protein to go up dramatically. This causes cancer cells to divide uncontrollably, leading to increased tumour formation.
Researchers used new powerful technology to genetically “silence” the protein and reduce the level of RBM3 in cancerous cells. The approach stopped cancer from growing and led to cell death. The new technique has been tested successfully on several types of cancers – breast, pancreas, colon, lung, ovarian and prostate.
“We are excited about this discovery because most cancers are thought to come from mutations in genes, and our studies, for the first time, have shown that too much of this type of protein actually causes normal cells to turn into cancer cells,” said Shrikant Anant, Ph.D., a cancer biologist at the OU Cancer Institute and principal investigator on the project.
Anant said they found RBM3 protein in every stage of many cancers, and the amount of protein increased as the cancer grew. The protein helped the cancer grow faster, avoid cell death and was part of the process that formed new blood vessels to feed the tumour.
“This process, called angiogenesis, is essential for tumour growth and suggests that targeting RBM3 may be an extremely powerful tool against many and perhaps all solid tumours,” Anant said.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.